Cell Proliferation

Cell Proliferation is a fully open access, online-only cell biology journal published by Wiley, founded in 1968 as Cell and Tissue Kinetics and renamed in 1991, covering cell proliferation, differentiation, stem cells and regenerative medicine, with a 2025 Journal Impact Factor of 7.6《细胞增殖》（Cell Proliferation）由（Wiley）出版，为纯在线完全开放获取细胞生物学刊，1968 年以《细胞与组织动力学》（Cell and Tissue Kinetics）创刊，1991 年改为现名，覆盖细胞增殖、分化、干细胞与再生医学，2025 年影响因子为 7.6。

Scope

• All aspects of cell proliferation and differentiation in normal and abnormal states form the historical core of the journal正常与异常状态下细胞增殖与分化的各个方面构成该刊的历史核心。
• Control systems and mechanisms operating at intercellular and intracellular level, at molecular and genetic resolution, are central细胞间与细胞内的控制系统与机制，在分子与遗传层面的研究处于中心位置。
• Modification of proliferation by chemical and physical agents, and interactions with such agents, are explicitly included化学与物理因素对增殖的修饰作用及二者相互作用被明确纳入。
• Mathematical modelling of cell populations and kinetic systems is treated as a legitimate research approach细胞群体与动力学系统的数学建模被视为正当研究路径。
• Development of new techniques, from lineage tracing to imaging and single-cell methods, is part of the remit新技术的开发属于该刊职责，从谱系追踪到成像与单细胞方法。
• Stem cells, gene editing, ageing, tissue engineering, cell therapy and clinical translation have become major growth areas干细胞、基因编辑、衰老、组织工程、细胞治疗与临床转化已成为主要增长方向。
• Cancer and stem cell biology are the two reference communities the journal most often serves肿瘤与干细胞生物学是该刊最常服务的两个参照群体。

History

• The journal began in 1968 as Cell and Tissue Kinetics, devoted to cellular proliferation and population kinetics and backed by three scientific societies该刊 1968 年以《细胞与组织动力学》创刊，专注细胞增殖与群体动力学，并由三个学会共同支持。
• After the societies surveyed the field and agreed that the scope should widen, it became Cell Proliferation from Volume 24 in January 1991三个学会征询学界意见并认定应拓宽范围后，该刊自 1991 年 1 月第 24 卷起更名为《细胞增殖》。^[1]
• The 50th anniversary in 2018 was marked by a tally of 50 volumes, more than 300 issues and over 2300 articles2018 年五十周年时，该刊已累计出版 50 卷、300 余期、2300 余篇论文。
• Qi Zhou of the Chinese Academy of Sciences took over as editor-in-chief in 2017, succeeding Catherine Sarraf, who had edited the journal from 2003（Qi Zhou）于 2017 年接任主编，前任（Catherine Sarraf）自 2003 年起主持该刊。
• In 2019 it became the flagship journal of the stem cell branch of the Chinese Society for Cell Biology, and in 2021 the Beijing Institute for Stem Cell and Regenerative Medicine began a long-term partnership with Wiley该刊 2019 年成为中国细胞生物学学会干细胞分会旗舰期刊，2021 年北京干细胞与再生医学研究院与（Wiley）建立长期合作。
• Its impact factor moved from 6.831 in 2021 to 8.755 in 2022, then 5.6 in 2024 and 7.6 in 2025, under a fully open access model在完全开放获取模式下，该刊影响因子由 2021 年的 6.831 升至 2022 年的 8.755，2024 年为 5.6，2025 年为 7.6。

Editors

• Qi Zhou, academician of the Chinese Academy of Sciences and a stem cell biologist, is editor-in-chief and has reshaped the journal around stem cells and regenerative medicine主编（Qi Zhou）为中国科学院院士、干细胞生物学家，推动该刊围绕干细胞与再生医学重塑。
• His predecessor Catherine Sarraf edited the journal from June 2003 to December 2017 and raised both its impact factor and its submission volume前任主编（Catherine Sarraf）自 2003 年 6 月至 2017 年 12 月主持该刊，提升了影响因子与投稿量。
• The journal reports a median of two days from submission to first decision and 67 days from submission to acceptance该刊公布投稿至首次决定的中位时间为 2 天，投稿至接收为 67 天。
• Article types include reviews, original research, case reports, stem cell standards and conference reports, a mix that reflects its clinical and standards-facing remit文章类型包括综述、原创研究、病例报告、干细胞标准与会议报告，反映其面向临床与标准的定位。
• The editorial board is drawn from the international stem cell and cell biology community, and the journal announced an expansion of the board in 2018 to cover new subject areas编委会来自国际干细胞与细胞生物学界，该刊 2018 年宣布扩充编委以覆盖新的学科方向。